Skip to content
Triangle logo TriangleGet started
← Hodgkin Lymphoma

NCT00393380 · STUDY IN CONTEXT

Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor

Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

Median time to neutrophil engraftment (defined as an absolute neutrophil count \[ANC\] greater than 500)

13 patients received the transplant.

→

secondary · POSTED

Cumulative Incidence of Acute GVHD Grades II-IV at day 100

13 patients were transplanted

→

secondary · POSTED

Cumulative Incidence of Chronic GVHD

13 patients were transplanted.

→

secondary · POSTED

Platelet engraftment (greater than 20,000)

13 patients were transplanted.

→

secondary · POSTED

100-day transplant-related mortality

13 patients were transplanted

→

secondary · POSTED

Cumulative Incidence of Relapse

13 patients were transplanted.

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record
trial
release id
clinical-indications-draft-1
disease state id
ds-hodgkin-lymphoma
nct id
NCT00393380
trial label
Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor
applicability
narrower
applicability note
Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
provenance class
registry-condition-search
discovery note
Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count
6
harms Count
1
qol Count
0
outcomes
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-hodgkin-lymphoma
    nct id
    NCT00393380
    outcome key
    om-0000
    source section id
    NCT00393380-om-0000
    source outcome index
    0
    endpoint
    Median Time to Neutrophil Engraftment (Defined as an Absolute Neutrophil Count [ANC] Greater Than 500)
    endpoint definition
    Median time to neutrophil engraftment (defined as an absolute neutrophil count \[ANC\] greater than 500)
    time origin
    Statistic is calculated at Day 42 but ANC counts are measured daily up through discharge.
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    13 patients received the transplant.
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-hodgkin-lymphoma
    nct id
    NCT00393380
    outcome key
    om-0001
    source section id
    NCT00393380-om-0001
    source outcome index
    1
    endpoint
    Cumulative Incidence of Acute GVHD Grades II-IV at Day 100
    endpoint definition
    Cumulative Incidence of Acute GVHD Grades II-IV at day 100
    time origin
    Measured at Day 100
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    13 patients were transplanted
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-hodgkin-lymphoma
    nct id
    NCT00393380
    outcome key
    om-0002
    source section id
    NCT00393380-om-0002
    source outcome index
    2
    endpoint
    Cumulative Incidence of Chronic GVHD
    endpoint definition
    Cumulative Incidence of Chronic GVHD
    time origin
    Measured at 2 years
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    13 patients were transplanted.
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  4. release id
    clinical-indications-draft-1
    disease state id
    ds-hodgkin-lymphoma
    nct id
    NCT00393380
    outcome key
    om-0003
    source section id
    NCT00393380-om-0003
    source outcome index
    3
    endpoint
    Platelet Engraftment (Greater Than 20,000)
    endpoint definition
    Platelet engraftment (greater than 20,000)
    time origin
    Measured at Day 180
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    13 patients were transplanted.
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  5. release id
    clinical-indications-draft-1
    disease state id
    ds-hodgkin-lymphoma
    nct id
    NCT00393380
    outcome key
    om-0004
    source section id
    NCT00393380-om-0004
    source outcome index
    4
    endpoint
    100-day Transplant-related Mortality
    endpoint definition
    100-day transplant-related mortality
    time origin
    Measured at Day 100
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    13 patients were transplanted
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  6. release id
    clinical-indications-draft-1
    disease state id
    ds-hodgkin-lymphoma
    nct id
    NCT00393380
    outcome key
    om-0005
    source section id
    NCT00393380-om-0005
    source outcome index
    5
    endpoint
    Cumulative Incidence of Relapse
    endpoint definition
    Cumulative Incidence of Relapse
    time origin
    Measured at 2 years
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    13 patients were transplanted.
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
arms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-hodgkin-lymphoma
    nct id
    NCT00393380
    outcome key
    om-0000
    arm key
    OG000
    arm label
    Parathyroid Hormone (Teriparatide)
    regimen
    Parathyroid hormone after double umbilical cord blood transplant.
    analyzed count
    13
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00393380-om-0000#groups/OG000
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-hodgkin-lymphoma
    nct id
    NCT00393380
    outcome key
    om-0001
    arm key
    OG000
    arm label
    Parathyroid Hormone (Teriparatide)
    regimen
    Parathyroid hormone after double umbilical cord blood transplant.
    analyzed count
    13
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00393380-om-0001#groups/OG000
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-hodgkin-lymphoma
    nct id
    NCT00393380
    outcome key
    om-0002
    arm key
    OG000
    arm label
    Parathyroid Hormone (Teriparatide)
    regimen
    Parathyroid hormone after double umbilical cord blood transplant.
    analyzed count
    13
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00393380-om-0002#groups/OG000
  4. release id
    clinical-indications-draft-1
    disease state id
    ds-hodgkin-lymphoma
    nct id
    NCT00393380
    outcome key
    om-0003
    arm key
    OG000
    arm label
    Parathyroid Hormone (Teriparatide)
    regimen
    Parathyroid hormone after double umbilical cord blood transplant.
    analyzed count
    13
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00393380-om-0003#groups/OG000
  5. release id
    clinical-indications-draft-1
    disease state id
    ds-hodgkin-lymphoma
    nct id
    NCT00393380
    outcome key
    om-0004
    arm key
    OG000
    arm label
    Parathyroid Hormone (Teriparatide)
    regimen
    Parathyroid hormone after double umbilical cord blood transplant.
    analyzed count
    13
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00393380-om-0004#groups/OG000
  6. release id
    clinical-indications-draft-1
    disease state id
    ds-hodgkin-lymphoma
    nct id
    NCT00393380
    outcome key
    om-0005
    arm key
    OG000
    arm label
    Parathyroid Hormone (Teriparatide)
    regimen
    Parathyroid hormone after double umbilical cord blood transplant.
    analyzed count
    13
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00393380-om-0005#groups/OG000
harms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-hodgkin-lymphoma
    nct id
    NCT00393380
    harm key
    EG000
    source section id
    NCT00393380-ae
    event group key
    EG000
    event group label
    Parathyroid Hormone (Teriparatide)
    serious affected
    8
    serious at risk
    13
    other affected
    8
    other at risk
    13
    frequency threshold
    5
    collection period
    2 years
    event definition
    Source null
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
quality of life
    setting source links

      Preserved source evidence · Not medical advice